Thomas H Tötterman Selected Research

Thomas H Tötterman Research Topics

Disease

26	Neoplasms (Cancer) 11/2021 - 10/2002
9	Melanoma (Melanoma, Malignant) 11/2021 - 05/2008
8	Urinary Bladder Neoplasms (Bladder Cancer) 03/2015 - 01/2005
5	Prostatic Neoplasms (Prostate Cancer) 01/2009 - 08/2004
4	Carcinoma (Carcinomatosis) 06/2010 - 01/2005
2	Adenocarcinoma 01/2014 - 06/2006
2	Cytokine Release Syndrome 01/2014 - 01/2008
2	Carcinoid Tumor (Carcinoid) 03/2008 - 01/2005
2	Breast Neoplasms (Breast Cancer) 03/2007 - 10/2004
1	Cholangiocarcinoma 11/2021
1	Ovarian Neoplasms (Ovarian Cancer) 11/2021
1	Relapsing-Remitting Multiple Sclerosis 10/2013
1	Non-Muscle Invasive Bladder Neoplasms 06/2010
1	Urinary Tract Infections (Urinary Tract Infection) 06/2010
1	Sepsis (Septicemia) 06/2010
1	Infections 05/2010
1	Opportunistic Infections (Opportunistic Infection) 05/2010
1	Thrombosis (Thrombus) 09/2009
1	Neoplasm Metastasis (Metastasis) 02/2009
1	Neuroendocrine Carcinoma 02/2009
1	Testicular Neoplasms (Testicular Cancer) 01/2005

Drug/Important Bio-Agent (IBA)

9	CD40 Ligand (CD40L)IBA 11/2021 - 05/2006
9	AntigensIBA 01/2014 - 05/2003
6	Proteins (Proteins, Gene)FDA Link 02/2009 - 08/2004
5	HLA-A*02:01 antigenIBA 01/2009 - 10/2004
4	Peptides (Polypeptides)IBA 01/2009 - 10/2004
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2021 - 04/2016
3	AntibodiesIBA 03/2015 - 01/2014
3	Interleukin-10 (Interleukin 10)IBA 09/2012 - 05/2006
3	LigandsIBA 04/2010 - 10/2002
3	EpitopesIBA 01/2009 - 10/2004
3	CytokinesIBA 01/2008 - 05/2006
2	Monoclonal AntibodiesIBA 01/2014 - 09/2012
2	Interleukin-12 (IL 12)IBA 09/2012 - 05/2006
2	Interferon-gamma (Interferon, gamma)IBA 05/2012 - 09/2008
2	Serotonin (5 Hydroxytryptamine)IBA 02/2009 - 01/2005
2	Messenger RNA (mRNA)IBA 03/2008 - 01/2007
2	TARPIBA 10/2004 - 08/2004
1	Interleukin-8 (Interleukin 8)IBA 11/2021
1	Bispecific AntibodiesIBA 01/2017
1	mitazalimabIBA 03/2015
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2014
1	Vaccine AdjuvantsIBA 01/2014
1	IgG Receptors (Fc gamma RI)IBA 01/2014
1	Interleukin-6 (Interleukin 6)IBA 09/2012
1	PotassiumIBA 06/2010
1	Antinuclear AntibodiesIBA 04/2010
1	Toll-Like Receptor AgonistsIBA 04/2010
1	Complement Inactivating AgentsIBA 09/2009
1	Transcription Factors (Transcription Factor)IBA 02/2009
1	antineoplaston A10 (A 10)IBA 02/2009
1	AMPA 2 glutamate receptor ionotropicIBA 02/2009
1	Ma2 antigenIBA 02/2009
1	Biomarkers (Surrogate Marker)IBA 02/2009
1	SerpinsIBA 02/2009
1	Odorant Receptors (Odorant Receptor)IBA 02/2009
1	CXC ChemokinesIBA 02/2009
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 02/2009
1	InterferonsIBA 01/2009
1	Interleukin-2 (IL2)IBA 09/2008
1	CDX2 Transcription FactorIBA 03/2008
1	Chromogranin AIBA 03/2008
1	AutoantigensIBA 03/2008
1	Tryptophan HydroxylaseIBA 03/2008
1	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA 03/2008
1	HLA Antigens (Human Leukocyte Antigens)IBA 03/2007
1	Complementary DNA (cDNA)IBA 03/2007
1	HLA-DR Antigens (HLA-DR)IBA 03/2007
1	Complement System Proteins (Complement)IBA 03/2007
1	Cancer VaccinesIBA 03/2007
1	HLA-A Antigens (HLA-A)IBA 03/2007
1	HLA-B Antigens (HLA-B)IBA 03/2007
1	Lymphotoxin-alpha (Lymphotoxin)IBA 01/2007
1	Transforming Growth Factor beta (TGF-beta)IBA 05/2006
1	SurvivinIBA 01/2005
1	OligodeoxyribonucleotidesIBA 01/2005
1	Therapeutic UsesIBA 01/2005
1	CPG-oligonucleotideIBA 01/2005
1	gamma-delta T-Cell Antigen Receptors (T-Cell Receptor delta-Chain)IBA 08/2004
1	Hormones (Hormone)IBA 08/2004
1	Testosterone (Sustanon)FDA Link 08/2004
1	AndrogensIBA 08/2004
1	VaccinesIBA 05/2003

Therapy/Procedure

17	Therapeutics 01/2021 - 08/2004
17	Immunotherapy 01/2021 - 10/2004
5	Injections 11/2021 - 06/2006
3	Aftercare (After-Treatment) 01/2021 - 05/2008
2	Cell- and Tissue-Based Therapy (Cell Therapy) 05/2012 - 03/2007
1	Radiotherapy 10/2017
1	Stem Cell Transplantation 10/2013
1	Bioreactors (Bioreactor) 02/2011
1	Cystectomy 06/2010
1	Organ Transplantation 05/2010
1	Lasers (Laser) 02/2009
1	Cytoreduction Surgical Procedures 05/2008